| PDL has six antibodies under clinical development – Daclizumab (for the treatment of asthma and multiple sclerosis), Visilizumab (for therapeutic benefit in autoimmune diseases, such as inflammatory bowel disease), Fontolizumab (for treatment for chronic autoimmune diseases such as Crohn's disease), Volociximab (for the treatment of cancers), Terlipressin and Ularitide. |